// App-Quantinova.ai

1019 : Investigation of cabozantinib, a MET and VEGFR2 inhibitor, on tumor metabolism and efficacy in a colorectal cancer patient-derived tumor explant model

Researchers

Presenter

  • Aaron J. Scott

Principal Investigators

  • Rachel Yahn

  • Stacey Bagby

  • Kendra Huber

  • Natalie Serkova

  • Wells Messersmith

  • John Arcaroli

Medical Centers

  • University of Colorado Hospital, Aurora, CO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • Kinase Insert Domain Receptor

Drug/Treatment

  • Cabozantinib

  • Regorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved